Inhibitors of apoptosis (IAPs) regulate intestinal immunity and inflammatory bowel disease (IBD) inflammation

Trends in Molecular Medicine

Volumn 20, Issue 11, 2014, Pages 652-665

  Pedersen, Jannie ^a   LaCasse, Eric C ^b   Seidelin, Jakob B ^a   Coskun, Mehmet ^a   Nielsen, Ole H ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b CHILDREN S HOSPITAL OF EASTERN ONTARIO   (Canada)

Author keywords

Anti apoptotic proteins; Inflammation; Inflammatory bowel disease; Intestine; Signaling pathways; Ubiquitin ligases

Indexed keywords

APOPTOSIS INHIBITOR; CASPASE RECRUITMENT DOMAIN PROTEIN 15; CASPASE RECRUITMENT DOMAIN PROTEIN 4; CIAP1 PROTEIN; CIAP2 PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INFLAMMASOME; INTERLEUKIN 1; NEW DRUG; NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN LIKE RECEPTOR; SURVIVIN; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG; X LINKED INHIBITOR OF APOPTOSIS; INHIBITOR OF APOPTOSIS PROTEIN;

CELL PROLIFERATION; CHROMOSOME MUTATION; CYTOKINE PRODUCTION; ENTERITIS; GENE MUTATION; HUMAN; IMMUNE DEFICIENCY; IMMUNITY; IMMUNOCOMPETENT CELL; IMMUNOPATHOGENESIS; INFLAMMATORY BOWEL DISEASE; INNATE IMMUNITY; INTESTINE CELL; NONHUMAN; REVIEW; SIGNAL TRANSDUCTION; X CHROMOSOME LINKED DISORDER; X LINKED LYMPHOPROLIFERATIVE DISEASE TYPE 2; ANIMAL; APOPTOSIS; DRUG DEVELOPMENT; DRUG EFFECTS; GENETICS; IMMUNOLOGY; INFLAMMATORY BOWEL DISEASES; INTESTINE; METABOLISM; MOLECULARLY TARGETED THERAPY; MULTIGENE FAMILY;

INTRACISTERNAL A-PARTICLES;

ANIMALS; APOPTOSIS; DRUG DISCOVERY; HUMANS; IMMUNITY, INNATE; INFLAMMATORY BOWEL DISEASES; INHIBITOR OF APOPTOSIS PROTEINS; INTESTINES; MOLECULAR TARGETED THERAPY; MULTIGENE FAMILY; SIGNAL TRANSDUCTION;

EID: 84909590335     PISSN: 14714914     EISSN: 1471499X     Source Type: Journal    
DOI: 10.1016/j.molmed.2014.09.006     Document Type: Review

References (122)

1. Baumgart D.C., Sandborn W.J. Crohn's disease. Lancet 2012, 380:1590-1605.
2. Ordas I., et al. Ulcerative colitis. Lancet 2012, 380:1606-1619.
3. Molodecky N.A., et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 2012, 142:46-54.
4. Maloy K.J., Powrie F. Intestinal homeostasis and its breakdown in inflammatory bowel disease. Nature 2011, 474:298-306.
5. Cominelli F. Cytokine-based therapies for Crohn's disease - new paradigms. N. Engl. J. Med. 2004, 351:2045-2048.
6. Corridoni D., et al. Inflammatory bowel disease. Immunol. Lett. 2014, 161:231-235.
7. Spehlmann M.E., et al. Epidemiology of inflammatory bowel disease in a German twin cohort: results of a nationwide study. Inflamm. Bowel Dis. 2008, 14:968-976.
8. Bengtson M.B., et al. Familial aggregation in Crohn's disease and ulcerative colitis in a Norwegian population-based cohort followed for ten years. J. Crohns Colitis 2009, 3:92-99.
9. Jostins L., et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature 2012, 491:119-124.
10. Mokry M., et al. Many inflammatory bowel disease risk loci include regions that regulate gene expression in immune cells and the intestinal epithelium. Gastroenterology 2014, 146:1040-1047.
11. Lees C.W., et al. New IBD genetics: common pathways with other diseases. Gut 2011, 60:1739-1753.
12. Abraham C., Cho J.H. Inflammatory bowel disease. N. Engl. J. Med. 2009, 361:2066-2078.
13. Cooney R., et al. NOD2 stimulation induces autophagy in dendritic cells influencing bacterial handling and antigen presentation. Nat. Med. 2010, 16:90-97.
14. van Heel D.A., et al. Muramyl dipeptide and toll-like receptor sensitivity in NOD2-associated Crohn's disease. Lancet 2005, 365:1794-1796.
15. Ogura Y., et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 2001, 411:603-606.
16. Plantinga T.S., et al. Crohn's disease-associated ATG16L1 polymorphism modulates pro-inflammatory cytokine responses selectively upon activation of NOD2. Gut 2011, 60:1229-1235.
17. Bertrand M.J., et al. Cellular inhibitors of apoptosis cIAP1 and cIAP2 are required for innate immunity signaling by the pattern recognition receptors NOD1 and NOD2. Immunity 2009, 30:789-801.
18. Krieg A., et al. XIAP mediates NOD signaling via interaction with RIP2. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:14524-14529.
19. Bertrand M.J., et al. cIAP1 and cIAP2 facilitate cancer cell survival by functioning as E3 ligases that promote RIP1 ubiquitination. Mol. Cell 2008, 30:689-700.
20. Scott F.L., et al. XIAP inhibits caspase-3 and -7 using two binding sites: evolutionarily conserved mechanism of IAPs. EMBO J. 2005, 24:645-655.
21. Mahoney D.J., et al. Both cIAP1 and cIAP2 regulate TNFalpha-mediated NF-kappaB activation. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:11778-11783.
22. Nielsen O.H., Ainsworth M.A. Tumor necrosis factor inhibitors for inflammatory bowel disease. N. Engl. J. Med. 2013, 369:754-762.
23. Nielsen O.H., Ainsworth M.A. Which biological agents are most appropriate for ulcerative colitis?. Ann. Intern. Med. 2014, 160:733-734.
24. Pedersen J., et al. Inflammatory pathways of importance for management of inflammatory bowel disease. World J. Gastroenterol. 2014, 20:64-77.
25. Conte D., et al. Inhibitor of apoptosis protein cIAP2 is essential for lipopolysaccharide-induced macrophage survival. Mol. Cell. Biol. 2006, 26:699-708.
26. Li H., et al. Ubiquitination of RIP is required for tumor necrosis factor alpha-induced NF-kappaB activation. J. Biol. Chem. 2006, 281:13636-13643.
27. Seidelin J.B., et al. Upregulation of cIAP2 in regenerating colonocytes in ulcerative colitis. Virchows Arch. 2007, 451:1031-1038.
28. Hui K.K., et al. Caspase-3 deficiency reveals a physiologic role for Smac/DIABLO in regulating programmed cell death. Cell Death Differ. 2011, 18:1780-1790.
29. Lu M., et al. XIAP induces NF-kappaB activation via the BIR1/TAB1 interaction and BIR1 dimerization. Mol. Cell 2007, 26:689-702.
30. Zarnegar B.J., et al. Noncanonical NF-kappaB activation requires coordinated assembly of a regulatory complex of the adaptors cIAP1, cIAP2, TRAF2 and TRAF3 and the kinase NIK. Nat. Immunol. 2008, 9:1371-1378.
31. Hinz M., et al. A cytoplasmic ATM-TRAF6-cIAP1 module links nuclear DNA damage signaling to ubiquitin-mediated NF-kappaB activation. Mol. Cell 2010, 40:63-74.
32. Xu M., et al. A ubiquitin replacement strategy in human cells reveals distinct mechanisms of IKK activation by TNFalpha and IL-1beta. Mol. Cell 2009, 36:302-314.
33. Dynek J.N., et al. c-IAP1 and UbcH5 promote K11-linked polyubiquitination of RIP1 in TNF signalling. EMBO J. 2010, 29:4198-4209.
34. Varfolomeev E., et al. IAP antagonists induce autoubiquitination of c-IAPs, NF-kappaB activation, and TNFalpha-dependent apoptosis. Cell 2007, 131:669-681.
35. Hagemann S., et al. Loss of survivin influences liver regeneration and is associated with impaired aurora B function. Cell Death Differ. 2013, 20:834-844.
36. Boman B.M., Fields J.Z. An APC:WNT counter-current-like mechanism regulates cell division along the human colonic crypt axis: a mechanism that explains how mutations induce proliferative abnormalities that drive colon cancer development. Front. Oncol. 2013, 3:1-15.
37. Kobayashi K., et al. Expression of a murine homologue of the inhibitor of apoptosis protein is related to cell proliferation. Proc. Natl. Acad. Sci. U.S.A. 1999, 96:1457-1462.
38. Tenthorey J.L., et al. Molecular basis for specific recognition of bacterial ligands by NAIP/NLRC4 inflammasomes. Mol. Cell 2014, 54:17-29.
39. Beug S.T., et al. Modulation of immune signalling by inhibitors of apoptosis. Trends Immunol. 2012, 33:535-545.
40. Kong F., et al. Role of positive selection in functional divergence of mammalian neuronal apoptosis inhibitor proteins during evolution. J. Biomed. Biotechnol. 2011, 2011:809765.
41. Gyrd-Hansen M., et al. IAPs contain an evolutionarily conserved ubiquitin-binding domain that regulates NF-kappaB as well as cell survival and oncogenesis. Nat. Cell Biol. 2008, 10:1309-1317.
42. Suryadinata R., et al. Mechanisms of generating polyubiquitin chains of different topology. Cells 2014, 3:674-689.
43. Palacios-Rodriguez Y., et al. Polypeptide modulators of caspase recruitment domain (CARD)-CARD-mediated protein-protein interactions. J. Biol. Chem. 2011, 286:44457-44466.
44. Lopez J., et al. CARD-mediated autoinhibition of cIAP1's E3 ligase activity suppresses cell proliferation and migration. Mol. Cell 2011, 42:569-583.
45. Feltham R., et al. IAPS and ubiquitylation. IUBMB Life 2012, 64:411-418.
46. Varfolomeev E., et al. Cellular inhibitors of apoptosis are global regulators of NF-kappaB and MAPK activation by members of the TNF family of receptors. Sci. Signal. 2012, 5:ra22.
47. Pobezinskaya Y.L., et al. The function of TRADD in signaling through tumor necrosis factor receptor 1 and TRIF-dependent Toll-like receptors. Nat. Immunol. 2008, 9:1047-1054.
48. Kanayama A., et al. TAB2 and TAB3 activate the NF-kappaB pathway through binding to polyubiquitin chains. Mol. Cell 2004, 15:535-548.
49. Napetschnig J., Wu H. Molecular basis of NF-kappaB signaling. Annu. Rev. Biophys. 2013, 42:443-468.
50. Coskun M., et al. MAP kinases in inflammatory bowel disease. Clin. Chim. Acta 2011, 412:513-520.
51. Hacker H., Karin M. Regulation and function of IKK and IKK-related kinases. Sci. STKE 2006, 2006:re13. 1-19.
52. Ben-Horin S., Chowers Y. Tailoring anti-TNF therapy in IBD: drug levels and disease activity. Nat. Rev. Gastroenterol. Hepatol. 2014, 11:243-255.
53. Neurath M.F., Travis S.P. Mucosal healing in inflammatory bowel diseases: a systematic review. Gut 2012, 61:1619-1635.
54. Grech A.P., et al. TRAF2 differentially regulates the canonical and noncanonical pathways of NF-kappaB activation in mature B cells. Immunity 2004, 21:629-642.
55. Liao G., et al. Regulation of the NF-kappaB-inducing kinase by tumor necrosis factor receptor-associated factor 3-induced degradation. J. Biol. Chem. 2004, 279:26243-26250.
56. Borcherding F., et al. The CD40-CD40L pathway contributes to the proinflammatory function of intestinal epithelial cells in inflammatory bowel disease. Am. J. Pathol. 2010, 176:1816-1827.
57. Danese S., et al. The CD40/CD40L costimulatory pathway in inflammatory bowel disease. Gut 2004, 53:1035-1043.
58. Vandenabeele P., Bertrand M.J. The role of the IAP E3 ubiquitin ligases in regulating pattern-recognition receptor signalling. Nat. Rev. Immunol. 2012, 12:833-844.
59. Kawai T., Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat. Immunol. 2010, 11:373-384.
60. Tseng P.H., et al. Different modes of ubiquitination of the adaptor TRAF3 selectively activate the expression of type I interferons and proinflammatory cytokines. Nat. Immunol. 2010, 11:70-75.
61. Correa R.G., et al. Roles of NOD1 (NLRC1) and NOD2 (NLRC2) in innate immunity and inflammatory diseases. Biosci. Rep. 2012, 32:597-608.
62. Tattoli I., et al. The Nodosome: Nod1 and Nod2 control bacterial infections and inflammation. Semin. Immunopathol. 2007, 29:289-301.
63. Bertrand M.J., et al. cIAP1/2 are direct E3 ligases conjugating diverse types of ubiquitin chains to receptor interacting proteins kinases 1 to 4 (RIP1-4). PLoS ONE 2011, 6:e22356.
64. Damgaard R.B., et al. The ubiquitin ligase XIAP recruits LUBAC for NOD2 signaling in inflammation and innate immunity. Mol. Cell 2012, 46:746-758.
65. Hasegawa M., et al. A critical role of RICK/RIP2 polyubiquitination in Nod-induced NF-kappaB activation. EMBO J. 2008, 27:373-383.
66. Cho J.H. The genetics and immunopathogenesis of inflammatory bowel disease. Nat. Rev. Immunol. 2008, 8:458-466.
67. Damgaard R.B., et al. Disease-causing mutations in the XIAP BIR2 domain impair NOD2-dependent immune signalling. EMBO Mol. Med. 2013, 5:1278-1295.
68. Neurath M.F. Cytokines in inflammatory bowel disease. Nat. Rev. Immunol. 2014, 14:329-342.
69. von Moltke J., et al. Rapid induction of inflammatory lipid mediators by the inflammasome in vivo. Nature 2012, 490:107-111.
70. Franchi L., et al. NLRC4-driven production of IL-1beta discriminates between pathogenic and commensal bacteria and promotes host intestinal defense. Nat. Immunol. 2012, 13:449-456.
71. Sellin M.E., et al. Epithelium-intrinsic NAIP/NLRC4 inflammasome drives infected enterocyte expulsion to restrict Salmonella replication in the intestinal mucosa. Cell Host Microbe 2014, 16:237-248.
72. Labbe K., et al. Cellular inhibitors of apoptosis proteins cIAP1 and cIAP2 are required for efficient caspase-1 activation by the inflammasome. Immunity 2011, 35:897-907.
73. Vince J.E., et al. Inhibitor of apoptosis proteins limit RIP3 kinase-dependent interleukin-1 activation. Immunity 2012, 36:215-227.
74. de Rivero Vaccari J.P., et al. A molecular platform in neurons regulates inflammation after spinal cord injury. J. Neurosci. 2008, 28:3404-3414.
75. Abulafia D.P., et al. Inhibition of the inflammasome complex reduces the inflammatory response after thromboembolic stroke in mice. J. Cereb. Blood Flow Metab. 2009, 29:534-544.
76. Koch S., Nusrat A. The life and death of epithelia during inflammation: lessons learned from the gut. Annu. Rev. Pathol. 2012, 7:35-60.
77. Newton K., Dixit V.M. Signaling in innate immunity and inflammation. Cold Spring Harb. Perspect. Biol. 2012, 4:1-19.
78. Schulzke J.D., et al. Disrupted barrier function through epithelial cell apoptosis. Ann. N. Y. Acad. Sci. 2006, 1072:288-299.
79. Ruemmele F.M., et al. The susceptibility to Fas-induced apoptosis in normal enterocytes is regulated on the level of cIAP1 and 2. Biochem. Biophys. Res. Commun. 2002, 290:1308-1314.
80. Seidelin J.B., Nielsen O.H. Expression profiling of apoptosis-related genes in enterocytes isolated from patients with ulcerative colitis. APMIS 2006, 114:508-517.
81. Seidelin J.B., Nielsen O.H. Attenuated apoptosis response to Fas-ligand in active ulcerative colitis. Inflamm. Bowel Dis. 2008, 14:1623-1629.
82. Bamba S., et al. Regulation of IL-11 expression in intestinal myofibroblasts: role of c-Jun AP-1- and MAPK-dependent pathways. Am. J. Physiol. Gastrointest. Liver Physiol. 2003, 285:G529-G538.
83. Naugler K.M., et al. Interleukin-11 antagonizes Fas ligand-mediated apoptosis in IEC-18 intestinal epithelial crypt cells: role of MEK and Akt-dependent signaling. Am. J. Physiol. Gastrointest. Liver Physiol. 2008, 294:G728-G737.
84. Rigaud S., et al. XIAP deficiency in humans causes an X-linked lymphoproliferative syndrome. Nature 2006, 444:110-114.
85. Filipovich A.H., et al. X-linked lymphoproliferative syndromes: brothers or distant cousins?. Blood 2010, 116:3398-3408.
86. Gifford C.E., et al. Clinical flow cytometric screening of SAP and XIAP expression accurately identifies patients with SH2D1A and XIAP/BIRC4 mutations. Cytometry B: Clin Cytom. 2014, 86:263-271.
87. Uhlig H.H. Monogenic diseases associated with intestinal inflammation: implications for the understanding of inflammatory bowel disease. Gut 2013, 62:1795-1805.
88. Zeissig Y., et al. XIAP variants in male Crohn's disease. Gut 2014, 63. 10.1136/gutjnl-2013-306520.
89. Aguilar C., et al. Characterization of Crohn disease in X-linked inhibitor of apoptosis-deficient male patients and female symptomatic carriers. J. Allergy Clin. Immunol. 2014, 10.1016/j.jaci.2014.04.031.
90. Conde C., et al. The inositol phosphatase SHIP-1 inhibits NOD2-induced NF-kappaB activation by disturbing the interaction of XIAP with RIP2. PLoS ONE 2012, 7:1-14.
91. Fiil B.K., et al. OTULIN restricts Met1-linked ubiquitination to control innate immune signaling. Mol. Cell 2013, 50:818-830.
92. Lipinski S., et al. RNAi screening identifies mediators of NOD2 signaling: implications for spatial specificity of MDP recognition. Proc. Natl. Acad. Sci. U.S.A. 2012, 109:21426-21431.
93. Gerart S., et al. Human iNKT and MAIT cells exhibit a PLZF-dependent proapoptotic propensity that is counterbalanced by XIAP. Blood 2013, 121:614-623.
94. Ruijing X., et al. Jalpha33+ MAIT cells play a protective role in TNBS induced intestinal inflammation. Hepatogastroenterology 2012, 59:762-767.
95. Serriari N.E., et al. Innate mucosal-associated invariant T (MAIT) cells are activated in inflammatory bowel diseases. Clin. Exp. Immunol. 2014, 176:266-274.
96. Ammann S., et al. A new functional assay for the diagnosis of X-linked inhibitor of apoptosis (XIAP) deficiency. Clin. Exp. Immunol. 2014, 176:394-400.
97. Xing Z., et al. Essential role of survivin, an inhibitor of apoptosis protein, in T cell development, maturation, and homeostasis. J. Exp. Med. 2004, 199:69-80.
98. Shon H.K., et al. Survivin reduces activation-induced T cell death in G1 phase. Mol. Cells 2003, 16:147-153.
99. de Souza H.S., et al. Increased levels of survivin, via association with heat shock protein 90, in mucosal T cells from patients with Crohn's disease. Gastroenterology 2012, 143:1017-1026.
100. Kim P.J., et al. Survivin and molecular pathogenesis of colorectal cancer. Lancet 2003, 362:205-209.
101. Dohi T., et al. Compartmentalized phosphorylation of IAP by protein kinase A regulates cytoprotection. Mol. Cell 2007, 27:17-28.
102. Petersen S.L., et al. Autocrine TNFalpha signaling renders human cancer cells susceptible to Smac-mimetic-induced apoptosis. Cancer Cell 2007, 12:445-456.
103. Yan Y., et al. Disturbed balance of expression between XIAP and Smac/DIABLO during tumour progression in renal cell carcinomas. Br. J. Cancer 2004, 91:1349-1357.
104. Cossu F., et al. Recognition of Smac-mimetic compounds by the BIR domain of cIAP1. Protein Sci. 2010, 19:2418-2429.
105. Foster D.M., et al. Proteasome inhibition of pathologic shedding of enterocytes to defend barrier function requires X-linked inhibitor of apoptosis protein and nuclear factor kappaB. Gastroenterology 2012, 143:133-144.
106. Kearney C.J., et al. Inhibitor of apoptosis proteins (IAPs) and their antagonists regulate spontaneous and tumor necrosis factor (TNF)-induced proinflammatory cytokine and chemokine production. J. Biol. Chem. 2013, 288:4878-4890.
107. Wong W.W., et al. cIAPs and XIAP regulate myelopoiesis through cytokine production in an RIPK and RIPK3 dependent manner. Blood 2014, 123:2562-2572.
108. Harikumar K.B., et al. K63-linked polyubiquitination of transcription factor IRF1 is essential for IL-1-induced production of chemokines CXCL10 and CCL5. Nat. Immunol. 2014, 15:231-238.
109. Tigno-Aranjuez J.T., et al. A discrete ubiquitin-mediated network regulates the strength of NOD2 signaling. Mol. Cell. Biol. 2013, 33:146-158.
110. Yabal M., et al. XIAP restricts TNF- and RIP3-dependent cell death and inflammasome activation. Cell Rep. 2014, 7:1796-1808.
111. Sikic B.I., et al. Safety, pharmacokinetics (PK), and pharmacodynamics (PD) of HGS1029, an inhibitor of apoptosis protein (IAP) inhibitor, in patients (Pts) with advanced solid tumors: results of a phase I study. J. Clin. Oncol. 2011, 29. 3008.
112. Erickson R.I., et al. Toxicity profile of small-molecule IAP antagonist GDC-0152 is linked to TNF-alpha pharmacology. Toxicol. Sci. 2013, 131:247-258.
113. Bauler L.D., et al. XIAP regulates cytosol-specific innate immunity to Listeria infection. PLoS Pathog. 2008, 4:e1000142.
114. Rumble J.M., et al. Phenotypic differences between mice deficient in XIAP and SAP, two factors targeted in X-linked lymphoproliferative syndrome (XLP). Cell. Immunol. 2009, 259:82-89.
115. Gentle I.E., et al. Inhibitors of apoptosis proteins (IAPs) are required for effective T-cell expansion/survival during antiviral immunity in mice. Blood 2014, 123:659-668.
116. Andree M., et al. BID-dependent release of mitochondrial SMAC dampens XIAP-mediated immunity against Shigella. EMBO J. 2014, 10.15252/embj.201387244.
117. McComb S., et al. cIAP1 and cIAP2 limit macrophage necroptosis by inhibiting Rip1 and Rip3 activation. Cell Death Differ. 2012, 19:1791-1801.
118. Robinson N., et al. Type I interferon induces necroptosis in macrophages during infection with Salmonella enterica serovar Typhimurium. Nat. Immunol. 2012, 13:954-962.
119. Beser O.F., et al. Inflammatory bowel disease with lethal disease course caused by a nonsense mutation in BIRC4 encoding X-linked inhibitor of apoptosis protein (XIAP). J Pediatr. Gastroenterol. Nutr. 2014, 10.1097/MPG.0000000000000504.
120. Marsh R.A., et al. Allogeneic hematopoietic cell transplantation for XIAP deficiency: an international survey reveals poor outcomes. Blood 2013, 121:877-883.
121. Speckmann C., et al. X-linked inhibitor of apoptosis (XIAP) deficiency: the spectrum of presenting manifestations beyond hemophagocytic lymphohistiocytosis. Clin. Immunol. 2013, 149:133-141.
122. Wada T., et al. Sustained elevation of serum interleukin-18 and its association with hemophagocytic lymphohistiocytosis in XIAP deficiency. Cytokine 2014, 65:74-78.